Carbetocin - Ferring Pharmaceuticals

Drug Profile

Carbetocin - Ferring Pharmaceuticals

Alternative Names: Duratobal; Duratocin; Lonactene; Pabal

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; Merck & Co; World Health Organization
  • Class Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Labour disorders

Most Recent Events

  • 27 Jun 2018 Efficacy data from the CHAMPION trial in Labour disorders released by Merck
  • 22 Feb 2018 Ferring Pharmaceuticals, Merck & Co and World Health Organization complete the CHAMPION trial in Labour disorders in Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and United Kingdom (ACTRN12614000870651)
  • 08 Apr 2015 A new room-temperature formulation of carbetocin receives approval through the EU Mutual Recognition Procedure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top